Cointime

Abalone Bio

company

About

Abalone Bio is an early stage biotech start-up that develops antibody drugs for the treatment of diseases.

  • 1 - 10

Highlights

Total Funding Amount
$1.32M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$225K
Industries
Biotechnology,Health Care,Product Research
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Abalone Bio is an early stage biotech start-up that develops antibody drugs for the treatment of diseases. The company uses libraries of yeast cells expressing billions of antibody variants to grow specific antibodies that can activate or inhibit a drug target, and also uses gene sequencing, machine learning, and synthetic biology to make recombinant protein versions of its antibodies and confirm their efficacy in human cell assays, allowing treatment of rare diseases with unique modes of action.

Abalone Bio was founded in 2017 and is headquartered in Richmond, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$1.32M
Abalone Bio has raised a total of $1.32M in funding over 2 rounds. Their latest funding was raised on Feb 28, 2019 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 28, 2019 Grant $1.09M 1 National Science Foundation — Detail
Dec 27, 2017 Grant $225K 1 National Science Foundation — Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Abalone Bio is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant
Cointime
Содержание
компания